Insulet Co. (NASDAQ:PODD) Given Average Recommendation of “Hold” by Analysts


Share on StockTwits

Shares of Insulet Co. (NASDAQ:PODD) have earned an average recommendation of “Hold” from the nineteen analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $250.06.

A number of equities analysts have recently issued reports on PODD shares. Wells Fargo & Company restated a “buy” rating on shares of Insulet in a research note on Friday, January 15th. Oppenheimer raised their price target on Insulet from $235.00 to $277.00 and gave the stock a “market perform” rating in a research note on Wednesday, March 3rd. BTIG Research restated a “hold” rating on shares of Insulet in a research note on Monday, February 1st. Piper Sandler downgraded Insulet from an “overweight” rating to a “neutral” rating and set a $260.00 price target on the stock. in a research note on Friday, January 29th. Finally, Raymond James raised their price target on Insulet from $282.00 to $296.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 2nd.

In other Insulet news, CEO Shacey Petrovic sold 15,000 shares of the firm’s stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $266.17, for a total transaction of $3,992,550.00. Following the sale, the chief executive officer now directly owns 56,589 shares of the company’s stock, valued at $15,062,294.13. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.10% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of PODD. Arcadia Investment Management Corp MI bought a new stake in shares of Insulet in the fourth quarter worth about $26,000. Steward Partners Investment Advisory LLC increased its holdings in shares of Insulet by 5,000.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 102 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 100 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Insulet in the fourth quarter worth about $28,000. Ellevest Inc. increased its holdings in shares of Insulet by 78.2% in the fourth quarter. Ellevest Inc. now owns 155 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 68 shares during the last quarter. Finally, SOA Wealth Advisors LLC. bought a new stake in shares of Insulet in the fourth quarter worth about $42,000.

PODD traded down $10.89 during trading on Tuesday, hitting $271.20. 12,665 shares of the company’s stock traded hands, compared to its average volume of 436,105. The company’s 50 day simple moving average is $278.62 and its two-hundred day simple moving average is $264.16. The company has a current ratio of 6.62, a quick ratio of 5.91 and a debt-to-equity ratio of 1.55. Insulet has a 12-month low of $164.40 and a 12-month high of $306.46. The stock has a market capitalization of $17.96 billion, a price-to-earnings ratio of 614.35 and a beta of 0.76.

Insulet (NASDAQ:PODD) last issued its earnings results on Monday, February 22nd. The medical instruments supplier reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.22). Insulet had a net margin of 3.33% and a return on equity of 8.94%. The business had revenue of $246.10 million for the quarter, compared to analysts’ expectations of $232.89 million. During the same quarter in the prior year, the business posted $0.08 earnings per share. The business’s revenue for the quarter was up 17.5% on a year-over-year basis. On average, equities analysts expect that Insulet will post 0.32 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager.

Further Reading: Limitations of the P/E Growth ratio

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.